Over the last 10 years Leap29 has made significant inroads in to establishing key relationships with some of the main organization directly affected by the capital expenditure in South East Asia. Working in partnership with both main contractors, vendors and end clients we have assisted some of the industry’s top talent into key positions for the delivery of both green field and brown field healthcare facilities throughout Singapore, Malaysia, China and India.
The Market Overview.
Asia pharmaceutical industry is currently valued at over $144 Billion and estimated to grow at a rate of 10.5 % year on year – This forecast is set to make Asia’s drug manufacturer’s prominent players in the global pharmaceutical industry
Singapore is currently the hub for pharmaceutical and life science in South East Asia. Over the last ten years it has developed some of the world’s most technologically advanced and state of the art pharmaceutical manufacturing facilities.
With the emergence of Singapore and the development of local talent and costs a number of organizations look to outsource manufacture to Malaysia which has found to incur a lower cost base and a highly trained local work force. Kuala Lumpur and Penang have seen this affect directly with industry growth figures in the country exceeding 11% per annum.
India ranks as the fourth largest manufacturer of drugs and medical devises with more than 80 FDA approved facilities – the most for any country outside the USA.
Moving Forwards
Leap29 have experienced significant growth in this sector and are looking forward to continually developing relationships with some of the industry’s key figures both locally in Asia and talent internationally seeking to gain experience in an up and coming hub for global pharmaceuticals.